Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
internal valuation cross-checks is overly optimistic on perpetual growth.
Intrinsic valuation suggests downside risk.
Danaher is a premier mature compounder in the life sciences and diagnostics space, characterized by the 'Danaher Business System' (DBS) which drives continuous margin improvement and highly successful M&A integration. With post-COVID revenue normalization nearing completion, the company is positioned for steady mid-single-digit organic growth, exceptionally high free cash flow conversion, and compounding returns through strategic capital allocation.
Danaher is a premier mature compounder in the life sciences and diagnostics space, characterized by the 'Danaher Business System' (DBS) which drives continuous margin improvement and highly successful M&A integration. With post-COVID revenue normalization nearing completion, the company is positioned for steady mid-single-digit organic growth, exceptionally high free cash flow conversion, and compounding returns through strategic capital allocation.
Switching Costs
Intrinsic valuation suggests downside risk.
Hold. Current valuation heavily credits future M&A, limiting near-term upside.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Under severe bioprocessing market contraction and failed M&A execution, our pure intrinsic models force valuation toward the $114-$122 range. Margins revert below 19% as DBS efficiencies fail to offset volume deleverage, and the terminal multiple contracts toward 15x as the compounding narrative breaks.
Switching Costs
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $5.2B after capex $1.1B, with terminal value at 65.7% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If bioprocessing organic growth > 5%, the M&A premium holds; if < 3%, multiple contraction accelerates.
If bioprocessing organic growth > 5%, the M&A premium holds; if < 3%, multiple contraction accelerates.
If bioprocessing organic growth > 5%, the M&A premium holds; if < 3%, multiple contraction accelerates.
If bioprocessing organic growth > 5%, the M&A premium holds; if < 3%, multiple contraction accelerates.
Currently exiting a severe post-COVID normalization trough; returning to normalized, structural growth trendlines.
Pharma R&D funding reaccelerates, inventory destocking concludes, driving high single-digit volume growth.
Sustained high rates crush early-stage biotech funding, causing prolonged capital equipment deferrals.
Currently exiting a severe post-COVID normalization trough; returning to normalized, structural growth trendlines.
Underweight/Neutral
Trim above $190 if organic growth fails to reaccelerate.
Intrinsic valuation suggests downside risk.
Hold. Danaher is a premier compounder, but current pricing fully embeds M&A success while ignoring near-term organic headwinds.
Upside case: internal valuation cross-checks is overly optimistic on perpetual growth. Downside case: Intrinsic valuation suggests downside risk.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Prolonged macro weakness in China and constrained global pharma/biotech funding dampen demand for life science and bioprocessing equipment, causing revenue growth to stagnate in the low-single digits. Margin expansion caps out, and the M&A compounding premium vanishes.
Extended pharma funding constraints and destocking cap revenue growth in low single-digits.
A major acquisition fails to realize DBS synergies, destroying ROIC and stalling margin expansion.
Deepening macro weakness and localized competition in China structurally erode regional market share and profitability.
The five developments that would weaken our investment case.
Declining recurring consumable sales indicates persistent bioprocessing customer destocking and biotech funding constraints, eliminating the predictable high-margin revenue streams that justify premium valuation multiples.
Current:Revenue growth was 2.9% for the period ended 2025-12-31.
Alert if< 0.0% over any trailing twelve-month period
Operating profitability falling indicates that Danaher Business System productivity gains cannot offset volume deleverage, compressing cash generation and disproving the structural margin expansion thesis.
Current:Operating margin was 19.1% for the period ended 2025-12-31.
Alert if< 18.0% over any trailing twelve-month period
Integration friction on large acquisitions destroys capital productivity, showing that acquired assets are failing to generate targeted synergy returns and impairing the core inorganic compounding strategy.
Current:ROIC was 4.9% as of the report's 2026-05-10 analysis date.
Alert if< 4.0% over any trailing twelve-month period
Product mix shifts and intensifying competition in regional markets squeeze gross profitability, undermining manufacturing cost advantages and signaling broader commercial pricing pressure across core life sciences instrumentation.
Current:Gross margin was 59.1% for the period ended 2025-12-31.
Alert if< 56.0% over any fiscal year
Cash flow conversion falling toward accounting profits indicates working capital buildup and slower cash realization, restricting the free cash flow deployment capacity needed for continuous programmatic acquisitions.
Current:Operating cash flow to net income was 1.775 as of the report's 2026-05-10 analysis date.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Bioprocessing end-markets recover faster than expected, and newly acquired assets (such as Abcam) are rapidly integrated via DBS, driving operating margins back above 22% and pushing EPS growth into the low-to-mid double digits. The market confidently prices in perpetual M&A success.
Post-COVID revenue normalization completes, yielding steady mid-single-digit organic growth and exceptionally high free cash flow conversion. DBS maintains operational discipline, but intrinsic valuation remains anchored by near-term multiple compression risks, landing at $163.10, roughly 35% below aggressive street internal valuation cross-checks.
Warning level: < 0.0% over any trailing twelve-month period. Declining recurring consumable sales indicates persistent bioprocessing customer destocking and biotech funding constraints, eliminating the predictable high-margin revenue streams that justify premium valuation multiples.
Warning level: < 18.0% over any trailing twelve-month period. Operating profitability falling indicates that Danaher Business System productivity gains cannot offset volume deleverage, compressing cash generation and disproving the structural margin expansion thesis.
Warning level: < 4.0% over any trailing twelve-month period. Integration friction on large acquisitions destroys capital productivity, showing that acquired assets are failing to generate targeted synergy returns and impairing the core inorganic compounding strategy.
Warning level: < 56.0% over any fiscal year. Product mix shifts and intensifying competition in regional markets squeeze gross profitability, undermining manufacturing cost advantages and signaling broader commercial pricing pressure across core life sciences instrumentation.
Warning level: < 1.20x over any trailing twelve-month period. Cash flow conversion falling toward accounting profits indicates working capital buildup and slower cash realization, restricting the free cash flow deployment capacity needed for continuous programmatic acquisitions.
| $24.80B |
| $26.64B |
| $23.89B |
| $23.88B |
| $24.57B |
| -0.2% |
| Gross profit | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B | -1.2% |
| Operating income | $6.74B | $7.35B | $5.33B | $4.92B | $4.50B | -9.6% |
| Net income | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B | -13.4% |
| EPS (diluted) | — | $9.66 | $6.38 | $5.29 | $5.05 | -19.4% |
| EBITDA | $8.80B | $9.48B | $7.50B | $7.28B | $6.95B | -5.8% |
| R&D | $1.50B | $1.53B | $1.50B | $1.58B | $1.60B | +1.6% |
| SG&A | $6.81B | $7.12B | $7.33B | $7.76B | $8.24B | +4.9% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 24,568,000,000 |
|---|---|
| Cost of revenue | 10,045,000,000 |
| Gross profit | 14,523,000,000 |
| Operating expenses | 9,833,000,000 |
| Operating income | 4,690,000,000 |
| Non-operating items and tax | -1,076,000,000 |
| Net income | 3,614,000,000 |
| Total assets | 83,464,000,000 |
|---|---|
| Cash | 4,615,000,000 |
| Current assets | 12,756,000,000 |
| Total liabilities | 30,923,000,000 |
| Current liabilities | 6,807,000,000 |
| Shareholders’ equity | 52,534,000,000 |
Point-in-time financial data used in the 2026-05-10 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 24.8B | 8.8B | 6.4B | 8.4B | 7.1B | 1.2B | 2.1B | 184M | 0 | 742M | 2B | — | — | — | — | 2.6B | 23.3B | 25.8% | — | 4.8% | — |
| 2022-12-31 | 26.6B | 9.5B | 7.2B | 8.5B | 7.4B | 1.1B | 2.1B | 295M | 0 | 818M | -1.7B | — | — | — | — | 6B | 20.6B | 28.3% | — | 7.4% | — |
| 2023-12-31 | 23.9B | 7.5B | 4.8B | 7.2B | 5.8B | 1.4B | 2.2B | 306M | 0 | 1.2B | -1.6B | — | — | — | — | 5.9B | 19.5B | 21.8% | — | 7.3% | — |
| 2024-12-31 | 23.9B | 7.3B | 3.9B | 6.7B | 5.3B | 1.4B | 2.4B | 288M | 6B | 768M | -1.7B | — | — | — | — | 2.1B | 17.1B | 20.4% | — | 7.9% | — |
| 2025-12-31 | 24.6B | 6.9B | 3.6B | 6.4B | 5.3B | 1.2B | 2.4B | 298M | 3.1B | 878M | 1B | — | — | — | — | 4.6B | 19.7B | 19.1% | — | 7.9% | — |
DHR trades at 18.8x forward earnings against a peer median of 17.6x; EV/EBITDA of 17.0x against a peer median of 18.8x; 6 peers.
Alert if< 1.20x over any trailing twelve-month period
| IDEXX Laboratories Inc. |
| 33.9x |
| 9.9x |
| 29.2x |
| 72.9% |
| 31.8% |
| WAT | Waters Corporation | 21.7x | 9.2x | 27.3x | 5.2% | 11.7% |
| A | Agilent Technologies Inc. | 17.6x | 4.6x | 17.5x | 19.9% | 22.9% |
| IQV | IQVIA Holdings Inc. | 12.6x | 1.8x | 14.7x | 22.5% | 13.6% |
